ALLO - Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit | Benzinga
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (NASDAQ:ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced it will participate in the TD Cowen 5th Annual Oncology Innovation Summit.
TD Cowen 5th Annual Oncology Innovation Summit
Tuesday, May 28, 2024
9:30am PT/12:30pm ET
The webcast will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section. Following a live webcast, a replay will be available on the Company's website for approximately 30 days.
About Allogene Therapeutics
Allogene Therapeutics, with headquarters in?South San Francisco, is a clinical-stage?biotechnology company pioneering the development of allogeneic chimeric antigen receptor T?cell (AlloCAR T™) products for cancer ...